| Healthy Skepticism | AdWatch Index | Introduction |
Please note this AdWatch issue is no longer active so you can not submit answers to the questions below.
Australia October 2003
Nexium (esomeprazole) from AstraZeneca

Source: Australian Family Physician September
2003: 2 page advertisement inside front cover.
|
Desire
Unfair comparisons
One of the comparisons is esomeprazole (Nexium) 40mg vs omeprazole (Losec, Acimax, Probitor) 20mg. (The dose of omeprazole is only disclosed in the fine print.) Omeprazole is a proton pump inhibitor that has been used for years to treat peptic ulcers and gastro-oesophageal reflux disease by reducing gastric acid levels. Omeprazole 20mg contains about 10mg of S-omeprazole and 10mg of its mirror molecule: R-omeprazole. Both S and R-omeprazole are converted to the same active drug that reduces production of gastric acid by proton pumps. R-omeprazole is absorbed into the body less than S-omeprazole and removed faster, so it may be less effective than S-omeprazole. Esomeprazole is just a different spelling for S-omeprazole. "Es" = "S-". AstraZeneca are using a different spelling that makes it less obvious that esomeprazole is just half of their old drug omeprazole (Losec). It is no surprise that 40mg S-omeprazole in Nexium 40mg is more effective than the 10mg of S-omeprazole plus 10mg of R-omeprazole. However a larger dose of omeprazole would be just as "powerful" as esomeprazole (Nexium) 40mg. The other comparison is esomeprazole (Nexium) 40mg vs lansoprazole (Zoton) 30mg. (Again the dose of lansoprazole is only disclosed in the fine print.) The graph below suggests that the difference in the percentage healed at 8 week is too small to be clinically significant.[3] Patients are unlikely to be able to detect a worthwhile difference in relief of symptoms. Missing comparisons The advertisement does not compare Nexium with other alternatives. The alternatives that should be considered include other proton pump inhibitors, other drugs and non-drug therapies.
We are not aware of any trials comparing esomeprazole with rabeprazole which is the only other proton pump inhibitor currently available in Australia.
General Recommendation There is no proven clinically significant efficacy or safety advantage of Nexium over fair comparison doses of other proton pump inhibitors. When a proton pump inhibitor is appropriate, use whichever is the cheapest at the time in the lowest dose that controls the symptoms. Current Recommendation for Australia
As doses increase prices increase but differences in efficacy diminish. The best value approach may be: · Commence therapy with lifestyle changes plus esomeprazole 20mg (Nexium). This will quickly control symptoms for most patients.[7] · If symptoms are not controlled try pantoprazole 40mg (Somac) before using esomeprazole 40mg (Nexium) as a last resort. · If symptoms are controlled then try lifestyle measures alone or add a H2 antagonist such as ranitidine (Multiple brands) or rabeprazole 10mg (Pariet) for maintenance. Further reading Do
Single Stereoisomer Drugs Provide Value? Jankowski
J, Jones R, Delaney B, Dent J. Feedback (Feedback will be provided to AstraZeneca and to regulatory agencies. We will take feedback seriously for improving future editions of AdWatch.) |
|
AdWatch is produced by Healthy Skepticism: www.healthyskepticism.org |
References
[1] Scott DK, Ferner RE. 'The strategy of desire' and rational prescribing. Brit J Clin Pharmacol 1994;37:217-219.
[2] Sutherland M. Advertising and the mind of the consumer. Sydney Allen & Unwin 1993
[3] Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002 Mar; 97(3):575-83.
[4] Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther. 2003 Sep 15;18(6):587-94.
[5] www.health.gov.au/pbs/healthpro/pricing/therelativity.pdf
and
Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther. 2001 Jul;23(7):998-1017.
[6] eTG Complete. Therapeutic Guidelines Ltd. Melbourne July 2003 www.tg.com.au
[7] Jankowski J, Jones R, Delaney B, Dent J. 10-minute consultation: Gastro-oesophageal reflux disease. BMJ. 2002 Oct 26;325(7370):945. http://bmj.bmjjournals.com/cgi/content/full/325/7370/945
| AdWatch is produced by Healthy Skepticism: www.healthyskepticism.org |